Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd is in the business of trading of pharmaceutical products[1]
- Market Cap ₹ 136 Cr.
- Current Price ₹ 254
- High / Low ₹ 316 / 175
- Stock P/E 44.8
- Book Value ₹ 49.5
- Dividend Yield 0.00 %
- ROCE 18.0 %
- ROE 14.2 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -5.72%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 6m | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 8.03 | 18.96 | 27.64 | |
| 7.09 | 16.59 | 23.39 | |
| Operating Profit | 0.94 | 2.37 | 4.25 |
| OPM % | 11.71% | 12.50% | 15.38% |
| 0.01 | 0.03 | 0.08 | |
| Interest | 0.00 | 0.09 | 0.18 |
| Depreciation | 0.00 | 0.01 | 0.02 |
| Profit before tax | 0.95 | 2.30 | 4.13 |
| Tax % | 26.32% | 26.09% | 26.15% |
| 0.70 | 1.70 | 3.04 | |
| EPS in Rs | 2.03 | 3.47 | 6.12 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 46% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 79% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 34% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 4.90 | 4.97 | |
| Reserves | 13.44 | 19.60 | |
| 1.60 | 3.26 | ||
| 0.94 | 3.02 | ||
| Total Liabilities | 20.88 | 30.85 | |
| 0.05 | 1.65 | ||
| CWIP | 0.00 | 0.00 | |
| Investments | 0.43 | 0.44 | |
| 20.40 | 28.76 | ||
| Total Assets | 20.88 | 30.85 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| -0.79 | 1.80 | ||
| -4.55 | -11.07 | ||
| 13.10 | 2.89 | ||
| Net Cash Flow | 7.77 | -6.39 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 90.48 | 117.79 | |
| Inventory Days | 6.27 | 53.66 | |
| Days Payable | 0.46 | 22.43 | |
| Cash Conversion Cycle | 96.29 | 149.02 | |
| Working Capital Days | 118.78 | 100.63 | |
| ROCE % | 18.04% |
Documents
Announcements
- Closure of Trading Window 1d
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Sep - Newspaper Publication pursuant to Regulation 30 and Regulation 47 of SEBI(LODR) Regulations,2015
-
Reg. 34 (1) Annual Report.
4 Sep - Annual Report FY2024-25 and AGM notice for 29 Sep 2025; audited financials and directors' report filed online and with BSE.
- Notice Of The 02Nd Annual General Meeting ('AGM') And Annual Report For The Financial Year 2024- 25 4 Sep
- Intimation Of 02Nd Annual General Meeting ('AGM') And Book Closure For AGM. 4 Sep
Business Overview:[1][2]
a) In FY23, Royal Traders, PHT, and Anaya merged to form a unified entity under the name Royal Sense Limited (RSL).
b) RSL supplies goods that meet international standards for hospitals, laboratories, institutions, and clinics. It offers a wide range of surgical accessories, tools, and equipment, which can be customized as per client requirements.
c) RSL specializes in medical device manufacturing as well as pharmaceuticals trading.
d) The company provides a comprehensive portfolio of products and services—from medical devices to essential drugs—catering to the diverse needs of healthcare providers and patients.